about
CBFB-MYH11 hypomethylation signature and PBX3 differential methylation revealed by targeted bisulfite sequencing in patients with acute myeloid leukemia.5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity.Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms.Estimation of molecular upper remission limit for monitoring minimal residual disease in peripheral blood of acute myeloid leukemia patients by WT1 expression.From cryptic chromosomal lesions to pathologically relevant genes: integration of SNP-array with gene expression profiling in myelodysplastic syndrome with normal karyotype.Transcription factors Fli1 and EKLF in the differentiation of megakaryocytic and erythroid progenitor in 5q- syndrome and in Diamond-Blackfan anemia.Relationship between Altered miRNA Expression and DNA Methylation of the DLK1-DIO3 Region in Azacitidine-Treated Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Myelodysplasia-Related ChangesHigh level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomideQuantitative monitoring of WT1 expression in peripheral blood before and after allogeneic stem cell transplantation for acute myeloid leukemia – a useful tool for early detection of minimal residual diseaseDecreased DNA methylation in acute myeloid leukemia patients with DNMT3A mutations and prognostic implications of DNA methylationDNA Methylation Validation Methods: a Coherent Review with Practical ComparisonPrognostic significance of mutation profile at diagnosis and mutation persistence during disease remission in adult acute myeloid leukaemia patientsDNA methylation and hydroxymethylation patterns in acute myeloid leukemia patients with mutations in DNMT3A and IDH1/2 and their combinations
P50
Q34340118-E22BCC34-25AE-40C5-ACE0-6956E80E87B4Q39395000-C0A83524-B5CB-49BF-BFAB-A74E6ADA629CQ39601934-27D213F8-1D84-4733-868B-5959749DADDBQ42324420-3B1E7A49-9495-4DF5-AFD9-FB3679C416D4Q45405305-056B87D9-0C01-4418-83FA-B53838DC6BFEQ46364652-D9821619-1AFA-4F6D-B3D8-05B1B30E0D13Q57157157-D7898941-4C7B-448A-BC05-E20B0945962BQ61074019-34930878-F6C8-4926-9611-150918B12121Q61074050-F182A1C3-1564-4D13-85FC-E02F787D9174Q61074063-21A03E6A-8231-48A5-8ADD-95D9CC71CEA5Q90468799-212F0588-5FBA-4D53-9999-446DE7660BB1Q92991650-AC2D21EF-D135-4888-A2D3-E43E0BDDF074Q93111055-AFED2F7D-9E4B-4144-8740-804A64CDF1B4
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Hana Hajkova
@ast
Hana Hajkova
@en
Hana Hajkova
@es
Hana Hajkova
@nl
Hana Hajkova
@sl
type
label
Hana Hajkova
@ast
Hana Hajkova
@en
Hana Hajkova
@es
Hana Hajkova
@nl
Hana Hajkova
@sl
prefLabel
Hana Hajkova
@ast
Hana Hajkova
@en
Hana Hajkova
@es
Hana Hajkova
@nl
Hana Hajkova
@sl
P1053
G-3708-2017
P106
P21
P31
P3829
P496
0000-0002-2967-8355